References
- Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551–565.
- Ebinger M, Witte KE, Ahlers J, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res 2010;34:1139–1142.
- Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol 2008;143:481–489.
- Castor A, Nilsson L, Astrand-Grundstrom I, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005;11:630–637.
- Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008;319: 336–339.
- Xu XJ, Tang YM, Shen HQ, et al. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia. Leuk Res 2012;36:1022–1027.
- Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000;95:1007–1013.
- George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(−) bone marrow progenitor population in children with acute lymphoblastic leukemia. Blood 2001;97:3925–3930.
- Quijano CA, Moore D 2nd,Arthur D, et al. Cytogenetically aberrant cells are present in the CD34 + CD33 − 38 − 19 − marrow compartment in children with acute lymphoblastic leukemia. Leukemia 1997;11:1508–1515.
- Hotfilder M, Rottgers S, Rosemann A, et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34 + CD19− cells. Cancer Res 2005;65:1442–1449.
- le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008;14:47–58.
- Kong Y, Yoshida S, Saito Y, et al. CD34 + CD38+ CD19 + as well as CD34 + CD38− CD19 + cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008;22:1207–1213.
- Wilson K, Case M, Minto L, et al. Flow minimal residual disease monitoring of candidate leukemic stem cells defined by the immunophenotype, CD34 + CD38lowCD19 + in B-lineage childhood acute lymphoblastic leukemia. Haematologica 2010;95:679–683.
- Digiuseppe JA. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy. Clin Lab Med 2007;27:533–549, vi.
- DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom 2009;76:150–155.